AU2002322270B2 - Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease - Google Patents

Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease Download PDF

Info

Publication number
AU2002322270B2
AU2002322270B2 AU2002322270A AU2002322270A AU2002322270B2 AU 2002322270 B2 AU2002322270 B2 AU 2002322270B2 AU 2002322270 A AU2002322270 A AU 2002322270A AU 2002322270 A AU2002322270 A AU 2002322270A AU 2002322270 B2 AU2002322270 B2 AU 2002322270B2
Authority
AU
Australia
Prior art keywords
cells
neural
cell
population
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002322270A
Other languages
English (en)
Other versions
AU2002322270A1 (en
Inventor
Melissa K. Carpenter
Jerrod J. Denham
Margaret S. Inokuma
Scott R. Thies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asterias Biotherapeutics Inc
Original Assignee
Asterias Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/888,309 external-priority patent/US20020019046A1/en
Application filed by Asterias Biotherapeutics Inc filed Critical Asterias Biotherapeutics Inc
Publication of AU2002322270A1 publication Critical patent/AU2002322270A1/en
Application granted granted Critical
Publication of AU2002322270B2 publication Critical patent/AU2002322270B2/en
Assigned to ASTERIAS BIOTHERAPEUTICS, INC. reassignment ASTERIAS BIOTHERAPEUTICS, INC. Request for Assignment Assignors: GERON CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1096—Processes for the isolation, preparation or purification of DNA or RNA cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/02—Drug screening
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
AU2002322270A 2001-06-21 2002-06-20 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease Ceased AU2002322270B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/888,309 US20020019046A1 (en) 2000-01-11 2001-06-21 Direct differentiation of human pluripotent stem cells and characterization of differentiated cells
US09/888,309 2001-06-21
US10/157,288 2002-05-28
US10/157,288 US7250294B2 (en) 2000-05-17 2002-05-28 Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
PCT/US2002/019477 WO2003000868A1 (en) 2001-06-21 2002-06-20 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease

Publications (2)

Publication Number Publication Date
AU2002322270A1 AU2002322270A1 (en) 2003-06-19
AU2002322270B2 true AU2002322270B2 (en) 2007-01-25

Family

ID=54328829

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002322270A Ceased AU2002322270B2 (en) 2001-06-21 2002-06-20 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease

Country Status (10)

Country Link
US (1) US7250294B2 (OSRAM)
EP (1) EP1404812B1 (OSRAM)
JP (4) JP4526265B2 (OSRAM)
KR (2) KR101247037B1 (OSRAM)
CN (1) CN100384986C (OSRAM)
AU (1) AU2002322270B2 (OSRAM)
CA (1) CA2451486C (OSRAM)
GB (1) GB2393733B (OSRAM)
IL (2) IL159324A0 (OSRAM)
WO (1) WO2003000868A1 (OSRAM)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US20050042749A1 (en) * 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
IL152741A0 (en) 2000-05-17 2003-06-24 Geron Corp Neural progenitor cell populations
US20030134422A1 (en) * 2002-01-16 2003-07-17 Sayre Chauncey Bigelow Stem cell maturation for all tissue lines
US20050090004A1 (en) * 2003-01-16 2005-04-28 Sayre Chauncey B. Stem cell maturation for all tissue lines
US20050170506A1 (en) * 2002-01-16 2005-08-04 Primegen Biotech Llc Therapeutic reprogramming, hybrid stem cells and maturation
EP2360241A1 (en) 2002-06-05 2011-08-24 ES Cell International Pte Ltd. Stem cells
US20050101014A1 (en) 2002-07-11 2005-05-12 Keirstead Hans S. Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
US20040224302A1 (en) * 2002-07-16 2004-11-11 Thomas Jessel Systems and methods for screening for modulators of neural differentiation
US7632679B2 (en) * 2002-07-16 2009-12-15 The Trustees Of Columbia University In The City Of New York Systems and methods for screening for modulators of neural differentiation
US8293488B2 (en) * 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
EP1572984B8 (en) 2002-12-16 2016-06-01 Technion Research & Development Foundation Ltd. Feeder-free, xeno-free culture system for human embryonic stem cells
ZA200401646B (en) * 2003-03-12 2004-06-07 Reliance Life Sciences Pvt Ltd Derivation of terminally differentiated dopaminergic neurons from human embryonic stem cells.
BRPI0408733A (pt) * 2003-03-12 2006-03-07 Reliance Life Sciences Pvt Ltd derivação de neurÈnios dopaminérgicos terminalmente diferenciados de células tronco embriÈnicas humanas
US7459152B2 (en) * 2003-04-23 2008-12-02 Rush University Medical Center Erythropoietin administration to improve graft survival
US7820439B2 (en) * 2003-09-03 2010-10-26 Reliance Life Sciences Pvt Ltd. In vitro generation of GABAergic neurons from pluripotent stem cells
EP1682075A4 (en) * 2003-11-07 2009-12-09 Univ Florida BREEDING AND DIFFERENTIATION OF NEURAL CREATOR CELLS
JP4481706B2 (ja) * 2004-03-31 2010-06-16 独立行政法人科学技術振興機構 脳梗塞疾患モデルマウス
JP5128946B2 (ja) * 2004-05-21 2013-01-23 ウィセル リサーチ インスティテュート インコーポレイテッド 胚性幹細胞のフィーダー非依存性長期培養
US20070020759A1 (en) * 2004-07-15 2007-01-25 Primegen Biotech Llc Therapeutic reprogramming of germ line stem cells
US20060188491A1 (en) * 2004-07-15 2006-08-24 Primegen Biotech, Llc Use of nuclear material to therapeutically reprogram differentiated cells
US20070196918A1 (en) * 2004-07-15 2007-08-23 Sayre Chauncey B Reprogramming of adult human testicular stem cells to pluripotent germ-line stem cells
US20060069008A1 (en) 2004-09-28 2006-03-30 Sanjay Mistry Treatment of neurological deficits in the striatum or substanta nigra pars compacta
DE602005002430T2 (de) 2004-09-30 2008-06-19 Reneuron Ltd., Guildford Zelllinie
US8257696B2 (en) * 2004-11-19 2012-09-04 University Of Florida Research Foundation, Inc. Indefinite culture of human adult glia without immortalization and therapeutic uses thereof
JP5560391B2 (ja) 2005-06-22 2014-07-23 アステリアス バイオセラピューティクス インコーポレイテッド ヒト胚性幹細胞の懸濁培養法
US20070015138A1 (en) * 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US8926959B2 (en) 2005-07-22 2015-01-06 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US8476070B2 (en) 2005-08-29 2013-07-02 Technion Research & Development Foundation Limited Media for culturing stem cells
GB0526664D0 (en) * 2005-11-30 2006-02-08 Plasticell Ltd Method
KR100838013B1 (ko) * 2006-06-07 2008-06-12 제일약품주식회사 인간배아줄기세포로부터 단계적 선별법을 통해 고수율로신경전구세포, 신경세포 및 기능성 도파민신경세포를생성하는 방법
US20080044847A1 (en) 2006-06-23 2008-02-21 Shusta Eric V Blood-Brain Barrier Model
ES2704401T3 (es) 2006-08-02 2019-03-18 Technion Res & Dev Foundation Métodos de expansión de células madre embrionarias en un cultivo en suspensión
WO2008086470A1 (en) 2007-01-10 2008-07-17 The Board Of Trustees Of The Leland Stanford Junior University System for optical stimulation of target cells
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
WO2008127974A1 (en) * 2007-04-13 2008-10-23 The Trustees Of Columbia University In The City Of New York Stem cell-based culture system for drug development
US9029147B2 (en) * 2007-06-15 2015-05-12 Massachusetts Institute Of Technology Methods and compositions for enhanced differentiation from embryonic stem cells
US10434327B2 (en) 2007-10-31 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Implantable optical stimulators
US8513009B2 (en) 2008-01-30 2013-08-20 Geron Corporation Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
MY169771A (en) 2008-04-23 2019-05-15 Univ Leland Stanford Junior Systems, methods and compositions for optical stimulation of target cells
BRPI0915583A2 (pt) 2008-06-17 2016-01-26 Univ Leland Stanford Junior aparelho e métodos para controle do desenvolvimento celular
US9101759B2 (en) 2008-07-08 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Materials and approaches for optical stimulation of the peripheral nervous system
US8969081B2 (en) * 2008-12-10 2015-03-03 The Trustees Of Columbia University In The City Of New York Caudal motor neuron derived from embryonic stem cells under conditions essentially free of any retinoid
EP2383334A4 (en) * 2009-01-23 2013-01-16 Univ Osaka FEEDER CELL FOR TARGET CELL INDUCTION
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
KR20120098573A (ko) * 2009-06-10 2012-09-05 브레인스템 바이오텍 리미티드 다분화능 기질 세포의 신경 분화용 방법, 시스템 및 조성물
WO2011005326A1 (en) 2009-07-09 2011-01-13 Massachusetts Institute Of Technology Methods and compositions for increased safety of stem cell-derived populations
CA2770753C (en) 2009-08-12 2019-01-15 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
US11261425B2 (en) 2009-08-12 2022-03-01 Kyoto University Method for inducing differentiation of pluripotent stem cells into neural precursor cells
US9018010B2 (en) 2009-11-12 2015-04-28 Technion Research & Development Foundation Limited Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
US20130059309A1 (en) * 2010-02-22 2013-03-07 Jian Feng Dopaminergic Neurons Derived From Induced Pluripotent Stem Cells and Method of Making Same
WO2011133661A2 (en) 2010-04-21 2011-10-27 Research Development Foundation Methods and compositions related to dopaminergic neuronal cells
CA2802087A1 (en) 2010-06-15 2011-12-22 Cellular Dynamics International, Inc. A compendium of ready-built stem cell models for interrogation of biological response
AU2011279250B2 (en) 2010-07-12 2014-12-04 California Institute Of Technology Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
CA2805773A1 (en) 2010-07-30 2012-02-02 Cambridge Enterprise Limited Corticogenesis of human pluripotent cells
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
CN106376525A (zh) 2010-11-05 2017-02-08 斯坦福大学托管董事会 记忆功能的控制和表征
EP2635341B1 (en) 2010-11-05 2018-08-08 The Board of Trustees of the Leland Stanford Junior University Upconversion of light for use in optogenetic methods
CA2816971A1 (en) 2010-11-05 2012-05-10 The Board Of Trustees Of The Leland Stanford Junior University Light-activated chimeric opsins and methods of using the same
CN103491770B (zh) 2010-11-05 2016-06-08 斯坦福大学托管董事会 稳定阶跃函数视蛋白及其使用方法
US8696722B2 (en) 2010-11-22 2014-04-15 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic magnetic resonance imaging
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US9670463B2 (en) 2011-10-14 2017-06-06 Children's Medical Center Corporation Inhibition and enhancement of reprogramming by chromatin modifying enzymes
CN113528442A (zh) * 2011-11-04 2021-10-22 纪念斯隆-凯特琳癌症中心 用于植入的中脑多巴胺（da）神经元
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
EP3524676A1 (en) 2011-12-16 2019-08-14 The Board of Trustees of The Leland Stanford Junior University Opsin polypeptides and methods of use thereof
EP2817068B1 (en) 2012-02-21 2017-04-12 The Board of Trustees of the Leland Stanford Junior University Compositions for treating neurogenic disorders of the pelvic floor
US9447378B2 (en) 2012-04-27 2016-09-20 Massachusetts Institute Of Technology Method for differentiating human embryonic stem cells into β-cells for the treatment of type I diabetes
CA2906756A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University Optogenetic control of behavioral state
EP3498824A1 (en) 2013-04-26 2019-06-19 Memorial Sloan-Kettering Cancer Center Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells
JP6549559B2 (ja) 2013-04-29 2019-07-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 標的細胞における活動電位の光遺伝学的調節のための装置、システム及び方法
WO2014201431A1 (en) 2013-06-14 2014-12-18 Massachusetts Institute Of Technology Articles and methods for stem cell differentiation
NZ716812A (en) * 2013-08-06 2022-04-29 Takeda Pharmaceuticals Co Method for producing dopaminergic neurons
CN105829538A (zh) 2013-08-14 2016-08-03 小利兰·斯坦福大学托管委员会 用于控制疼痛的组合物和方法
US10202580B2 (en) 2014-01-21 2019-02-12 Japan Science And Technology Agency Adult oligodendrocyte-type 2 astrocyte progenitor cell production method
DK3119881T3 (da) 2014-03-21 2023-04-03 Fujifilm Cellular Dynamics Inc Production of midbrain dopaminergic neurons and methods for the use thereof
WO2015164740A1 (en) 2014-04-24 2015-10-29 Board Of Regents, The University Of Texas System Application of induced pluripotent stem cells to generate adoptive cell therapy products
EP3174975B1 (en) * 2014-07-31 2020-09-16 Université d'Aix-Marseille Method for generating neuronal and muscular cells
JP6983069B2 (ja) * 2014-10-20 2021-12-17 ニューラルステム， インコーポレイテッド 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法
JP6686361B2 (ja) * 2014-11-26 2020-04-22 東ソー株式会社 細胞回収のための標本作製方法
KR101695429B1 (ko) * 2015-10-15 2017-01-12 한국과학기술연구원 생체외에서 운동 신경세포의 배양 촉진을 위한 코엔자임 q10을 포함하는 조성물
FR3058892B1 (fr) * 2016-11-23 2021-04-09 Univ Bordeaux Unite de tissu neural et utilisation d'une telle unite pour l'implantation dans le systeme nerveux d'un mammifere
WO2019107481A1 (ja) * 2017-11-30 2019-06-06 国立大学法人京都大学 細胞興奮毒性評価方法
CN115397837A (zh) * 2020-04-13 2022-11-25 株式会社岛津制作所 分化诱导用肽
EP4477746A4 (en) 2022-02-09 2026-02-18 Racthera Co Ltd METHOD FOR EVALUATING THE DIFFERENTIATION POTENTIAL OF CELLS IN A CULTURE BROTH IN THE DIFFERENCE OF MULTIPOTENTED STEM CELLS INTO NEURAL CELLS OF THE MENSCEPHAL FLOOR PLAQUE REGION
KR20230145820A (ko) 2022-04-11 2023-10-18 재단법인대구경북과학기술원 미세 유체 채널 장치, 이를 이용한 약물 스크리닝 시스템 및 그 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US23376A (en) * 1859-03-29 Improvement in harvesters
US4491632A (en) 1979-10-22 1985-01-01 The Massachusetts General Hospital Process for producing antibodies to hepatitis virus and cell lines therefor
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
DE3167442D1 (en) 1980-07-07 1985-01-10 Nat Res Dev Improvements in or relating to cell lines
GB2197915B (en) 1986-11-19 1990-11-14 Rolls Royce Plc Improvements in or relating to fluid bearings
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
AU667680B2 (en) * 1991-08-07 1996-04-04 Albert Einstein College Of Medicine Of Yeshiva University Proliferation of hepatocyte precursors
US5654183A (en) 1992-07-27 1997-08-05 California Institute Of Technology Genetically engineered mammalian neural crest stem cells
US5849553A (en) * 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
US5672499A (en) * 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
WO1994003199A1 (en) 1992-08-04 1994-02-17 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
US5766948A (en) * 1993-01-06 1998-06-16 The Regents Of The University Of California Method for production of neuroblasts
US5534404A (en) * 1993-12-10 1996-07-09 Cytotherapeutics, Inc. Glucose responsive insulin secreting β-cell lines and method for producing same
US5639618A (en) * 1994-05-13 1997-06-17 Plurion, Inc. Method of isolating a lineage specific stem cell in vitro
US5476975A (en) * 1994-07-08 1995-12-19 Ruddick; John N. R. Extraction of toxic organic contaminants from wood and photodegradation of toxic organic contaminants
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5753506A (en) * 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
CN1254376A (zh) 1996-10-01 2000-05-24 杰龙公司 端粒酶逆转录酶
AU5734998A (en) 1997-01-10 1998-08-03 Life Technologies, Inc. Embryonic stem cell serum replacement
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US6361996B1 (en) 1997-05-07 2002-03-26 University Of Utah Research Foundation Neuroepithelial stem cells and glial-restricted intermediate precursors
WO1999001159A1 (en) 1997-07-04 1999-01-14 University Of Utah Research Foundation Lineage-restricted neuronal precursors
US6235527B1 (en) 1997-11-29 2001-05-22 University Of Utah Research Foundation Lineage restricted glial precursors from the central nervous system
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US5852832A (en) 1997-08-20 1998-12-29 Voigt; Tricia Anne Portable toilet seat
US5968829A (en) * 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
JP3880795B2 (ja) 1997-10-23 2007-02-14 ジェロン・コーポレーション フィーダー細胞を含まない培養物中で、霊長類由来始原幹細胞を増殖させるための方法
DE19756864C5 (de) * 1997-12-19 2014-07-10 Oliver Brüstle Neurale Vorläuferzellen, Verfahren zu ihrer Herstellung und ihre Verwendung zur Therapie von neuralen Defekten
JP2002504362A (ja) 1998-02-27 2002-02-12 メディカル・カレッジ・オブ・ハンプトン・ローズ 移植治療のための前駆胚幹細胞からの細胞および組織の誘導体
US6812027B2 (en) * 1998-03-25 2004-11-02 Cornell Research Foundation, Inc. Discovery, localization, harvest, and propagation of an FGF2 and BDNF-responsive population of neural and neuronal progenitor cells in the adult human forebrain
CA2324591A1 (en) 1998-04-09 1999-10-21 Bresagen Limited Cell differentiation/proliferation and maintenance factor and uses thereof
JP3291698B2 (ja) * 1998-07-24 2002-06-10 スティーブン・カーティン 可変眼鏡用レンズ
AU755849B2 (en) 1998-09-22 2002-12-19 Neuralstem Biopharmaceuticals, Ltd. Stable neural stem cell lines
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
IL143892A0 (en) * 1998-12-21 2002-04-21 Univ Monash Kidney disease detection and treatment
US6087168A (en) * 1999-01-20 2000-07-11 Cedars Sinai Medical Center Conversion of non-neuronal cells into neurons: transdifferentiation of epidermal cells
AU780256B2 (en) 1999-02-12 2005-03-10 Boco Silicon Valley, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US6238922B1 (en) * 1999-02-26 2001-05-29 Stemcells, Inc. Use of collagenase in the preparation of neural stem cell cultures
JP2002538820A (ja) * 1999-03-17 2002-11-19 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション ミクロクローンのクローニングされていないｃＤＮＡライブラリーの作製および使用
AU2913801A (en) 1999-12-23 2001-07-03 Cornell Research Foundation Inc. A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells
CA2397292A1 (en) 2000-01-14 2001-07-19 Bresagen Limited Cell production
US6602711B1 (en) * 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
WO2001068815A1 (en) 2000-03-14 2001-09-20 Es Cell International Pte Ltd Embryonic stem cells and neural progenitor cells derived therefrom
US6458589B1 (en) * 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
WO2001083715A2 (en) 2000-05-01 2001-11-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary, Derivation of midbrain dopaminergic neurons from embryonic stem cells
US8273570B2 (en) * 2000-05-16 2012-09-25 Riken Process of inducing differentiation of embryonic cell to cell expressing neural surface marker using OP9 or PA6 cells
IL152741A0 (en) * 2000-05-17 2003-06-24 Geron Corp Neural progenitor cell populations
JP4795616B2 (ja) * 2000-06-20 2011-10-19 イーエス・セル・インターナショナル・プライヴェート・リミテッド Ｂｍｐ−２経路アンタゴニストの存在下においてｅｓ細胞を培養することによって胚性幹細胞の分化をコントロールする方法
JP3660601B2 (ja) 2001-03-30 2005-06-15 独立行政法人科学技術振興機構 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法
US20040247571A1 (en) 2001-04-23 2004-12-09 Xia Meijer Neural cells expressing tyrosine hydroxylase
US7285415B2 (en) 2002-07-11 2007-10-23 The Regents Of The University Of California Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
HU227443B1 (en) 2007-10-18 2011-06-28 Pannon Egyetem Multifunction-compatibilisation package of additives for plastic and rubber compositions

Also Published As

Publication number Publication date
GB2393733B (en) 2005-09-14
CN1630713A (zh) 2005-06-22
JP2018029604A (ja) 2018-03-01
EP1404812B1 (en) 2018-01-24
WO2003000868A1 (en) 2003-01-03
JP2013059336A (ja) 2013-04-04
JP4526265B2 (ja) 2010-08-18
KR20040044415A (ko) 2004-05-28
IL159324A0 (en) 2004-06-01
EP1404812A4 (en) 2005-01-19
US20030103949A1 (en) 2003-06-05
JP2015180211A (ja) 2015-10-15
EP1404812A1 (en) 2004-04-07
CA2451486C (en) 2019-09-24
KR20090104923A (ko) 2009-10-06
US7250294B2 (en) 2007-07-31
IL159324A (en) 2012-04-30
CN100384986C (zh) 2008-04-30
GB2393733A (en) 2004-04-07
JP2004533835A (ja) 2004-11-11
KR101247037B1 (ko) 2013-03-25
GB0400167D0 (en) 2004-02-11
CA2451486A1 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
CA2451486C (en) Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease
AU2002322270A1 (en) Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease
AU2001263199B2 (en) Neural progenitor cell populations
AU2001263199A1 (en) Neural progenitor cell populations
JP5159804B2 (ja) パーキンソン病を治療するためのドーパミン作動性ニューロンおよび増殖能のある前駆細胞
US7763463B2 (en) Use of cyclic AMP and ascorbic acid to produce dopaminergic neurons from embryonic stem cells
AU2004214542B2 (en) Neural progenitor cell populations
HK1075673B (en) Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease

Legal Events

Date Code Title Description
CB Opposition filed

Opponent name: ES CELL INTERNATIONAL PTE LTD

CH Opposition withdrawn

Opponent name: ES CELL INTERNATIONAL PTE LTD

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ASTERIAS BIOTHERAPEUTICS, INC.

Free format text: FORMER OWNER WAS: GERON CORPORATION

MK14 Patent ceased section 143(a) (annual fees not paid) or expired